Volume: 5 Issue: 2
Year: 2017, Page: 25-28,
Introduction: HIV positive people were frequently infected with Hepatitis B virus and total global estimate of people with co-infection is around 2 to 4 million. All people who were infected with HIV should be screened for HBV co-infection which poses a main threat for development of Cirrhosis and Hepatocellular carcinoma.
Objectives: The main objective of the current study is to assess the incidence of Hepatitis B co-infection in HIV infected patients of rural background attending a tertiary care setup.
Materials & Methods :This is a cross-sectional study done over a period of one year among the outpatients attending Prathima Hospital. Ethical clearance was taken from institutional ethical committee. Both HIV and HBsAg screening were done by using rapid immunoassay. The results were calculated by using SPSS 16 software.
Results : In our study there is no significant gender difference in the mean age of population who were infected with HIV (P=0.442). Total 16.98% of patients with HIV positive were screened positive for HBsAg indicating co-infection among the rural population attending our tertiary care center.
Conclusion :HIV infected individuals are more prone for HBV infection and are at increased risk for subsequent co-infection by Hepatitis B virus. All the HIV infected individuals and their family members should be encouraged for routine HBV screening at least half yearly. Patients with co-infection should be effectively and systematically treated with combined HBV and ART (antiretroviral therapy).
Keywords: HIV, HBV co-infection, Cirrhosis, Hepatocellular carcinoma, Antiretroviral therapy.
1. Goldin RD, Fish DE, Hay A, Waters JA, McGarvey MJ, Main J, Thomas HC: Histological and immunohistochemical study of hepatitis B virus in human immunodeficiency virus infection. J Clin Pathol 1990, 43:203–205.
2. Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P: Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology 1999, 29:1306–1310.
3. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Muñoz A, Thomas DL, Multicenter AIDS Cohort Study: HIV1, hepatitis B virus, and risk of liverrelated mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921–1926.
4. Piroth L, Sène D, Pol S, Goderel I, Lacombe K, Martha B, Rey D, Loustau-Ratti V, Bergmann JF, Pialoux G, Gervais A, Lascoux-Combe C, Carrat F, Cacoub P:Eidemiology, diagnosis and treatment of chronic hepatitis B in HIVinfected patients (EPIB 2005 STUDY). AIDS 2007, 21:1323–1331.
5. Alter MJ. Epidemiology of viral hepatitis and HIV coinfection. J Hepatol. 2006; 44:S6–9.
6. World Health Organization, Global Observatory Data 2013, [http://www.who.int/gho/hiv/en/]
7. World Health Organization, Hepatitis B Fact sheet revised July 2014, [http://www.who.int/mediacentre/factsheets/ fs204/en/]
8. Shapiro CN. Transmission of hepatitis viruses. Ann Intern Med. 1994;120:82–4.
9. Ranjbar R, Davari A, Izadi M, Jonaidi N, Alavian SM. HIV/ HBV coinfections: epidemiology, natural history, and treatment: a review article. Iran Red Crescent Med J. 2011;13(12):855–62.
10. Owolabi LF, Ibrahim A, Musa BM, Gwaram BA, Dutse AI, et al. Prevalence and burden of human immunodeficiency virus and hepatitis B virus coinfection in Nigeria: a systematic review and meta-analysis. J AIDS Clin Res. 2014;5:308.
11. Matthews PC, Geretti AM, Goulder PJ, Klenerman P. Epidemiology and impact of HIV coinfection with hepatitis B and hepatitis C viruses in sub- Saharan Africa. J Clin Virol. 2014;61(1):20–33.
12. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, Matchaba G, et al. Impact of lamivudine on HIV and hepatitis B virusrelated outcomes in HIV/ hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS. 2011;25:1727–35.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
14. Current guidelines. AIDSinfo: Clinical Guidelines Portal. http://www.aidsinfo. nih.gov/guidelines. Updated and accessed November 6, 2014.
15. Guidelines, Version 7.02. European AIDS Clinical Society. http://www.europeanaidsclinicalsociety.org. Updated June 2014. Accessed November 6, 2014.
16. Jing Xie, Yang Han, Zhifeng Qiu, Yijia Li, Yanling Li, Xiaojing Song, et al. Prevalence of hepatitis B and C viruses in HIVpositive patients in China: a cross-sectional study. Journal of the International AIDS Society 2016, 19:206-59.
17. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com, updated 2013/04/06, accessed 2015/ 10/09.
18. Bùi Vu Huy, Kanxay Vernavong, and Nguy?n Van Kính, “HBV and HCV Coinfection among HIV/AIDS Patients in the National Hospital of Tropical Diseases, Vietnam,” AIDS Research and Treatment, vol. 2014, Article ID 581021, 5 pages, 2014. doi:10.1155/2014/581.
19. Bagheri Amiri F, Mostafavi E, Mirzazadeh A. HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11(3): e0151946. doi:10.1371/journal. pone.0151946.
20. David M Iser and Sharon R Lewin. Future directions in the treatment of HIV–HBV coinfection. HIV Ther. 2009 July 1; 3(4): 405–415.
21. DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. AIDS info website 2013.http://aidsinfo.nih.gov/contentfiles/lvguidelines/ AdultandAdolescentGL.pdf
22. Narayan Dharel and R K Sterling. Hepatitits B Virus-HIV Coinfection: forgotten but not gone. Gastroentrology & Hepatology. 2014 Dec 10(12): 780-788.
Ritu Vaish. Study of coinfection of HBV and HIV in patients attending a tertiary care teaching hospital.Perspectives in Medical Research 2017;5(2):25-28.